These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 32718811)

  • 41. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients.
    Moten AS; Zhao H; Intenzo CM; Willis AI
    Eur J Surg Oncol; 2019 Nov; 45(11):2090-2095. PubMed ID: 31253543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
    Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
    Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection.
    Laird AM; Gauger PG; Miller BS; Doherty GM
    World J Surg; 2012 Jun; 36(6):1268-73. PubMed ID: 22270997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
    Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
    Zhao H; Gong Y
    Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of completion thyroidectomy followed by radioactive iodine ablation for patients with lymph node recurrence of papillary thyroid carcinoma.
    Saito Y; Matsuzu K; Sugino K; Takami H; Kitagawa W; Nagahama M; Ito K
    Surgery; 2019 Sep; 166(3):342-348. PubMed ID: 31128851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A UK based two-centre review of multifocality and its role in the treatment of papillary thyroid cancer.
    Li LQ; Hey SY; Andreeva D; Tornari C; Sawant R; Harding NE; Adamson R; Hay A; Simo R; Nixon IJ
    Eur J Surg Oncol; 2022 Jan; 48(1):14-20. PubMed ID: 34253424
    [TBL] [Abstract][Full Text] [Related]  

  • 50. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report.
    Thewjitcharoen Y; Krittiyawong S; Butadej S; Nakasatien S; Polchart S; Junyangdikul P; Kanchanapituk A; Himathongkam T
    Medicine (Baltimore); 2020 Apr; 99(16):e19892. PubMed ID: 32312017
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
    Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
    Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.
    Ito Y; Miyauchi A; Masuoka H; Fukushima M; Kihara M; Miya A
    World J Surg; 2018 Aug; 42(8):2462-2468. PubMed ID: 29372373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
    Horiuchi K; Fujimoto M; Hidenori K; Yoshida Y; Noguchi E; Omi Y; Okamoto T
    World J Surg; 2023 Oct; 47(10):2464-2473. PubMed ID: 37266697
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of radioactive iodine in the management of patients with differentiated thyroid cancer - An oncologic surgical perspective.
    Nixon IJ; Shah JP; Zafereo M; Simo RS; Hay ID; Suárez C; Zbären P; Rinaldo A; Sanabria A; Silver C; Mäkitie A; Vander Poorten V; Kowalski LP; Shaha AR; Randolph GW; Ferlito A
    Eur J Surg Oncol; 2020 May; 46(5):754-762. PubMed ID: 31952928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Impact of Pathologically Positive Lymph Nodes in the Clinically Negative Neck: An Analysis of 39,301 Patients with Papillary Thyroid Cancer.
    Ruel E; Thomas S; Perkins JM; Roman SA; Sosa JA
    Ann Surg Oncol; 2017 Jul; 24(7):1935-1942. PubMed ID: 28127652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term efficacy of lobectomy for stage T1 papillary thyroid carcinoma with varying degrees of lymph node metastasis.
    Qin C; Cai S; Qi Y; Liu M; Xu W; Yin M; Tang H; Ji Q; Liao T; Wang Y
    Front Endocrinol (Lausanne); 2024; 15():1453601. PubMed ID: 39175578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma.
    McDow AD; Shumway CM; Pitt SC; Schneider DF; Sippel RS; Long KL
    Ann Surg Oncol; 2019 Nov; 26(12):4002-4007. PubMed ID: 31267301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer--a randomized controlled trial.
    Sawka AM; Straus S; Brierley JD; Tsang RW; Rotstein L; Rodin G; Gafni A; Ezzat S; Thabane L; Thorpe KE; Goldstein DP
    Trials; 2010 Jul; 11():81. PubMed ID: 20659341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.